Literature DB >> 10962441

Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours.

D Zwahlen1, M P Tschan, T J Grob, U R Peters, D Fink, W Haenggi, H J Altermatt, J F Cajot, A Tobler, M F Fey, S Aebi.   

Abstract

The p73 gene encodes a protein with substantial structural and functional similarities to the tumour-suppressor p53. Alternative splicing of p73 mRNA leads to expression of 6 known RNA species and proteins (alpha, beta, gamma, delta, epsilon, zeta). We analysed the expression of these splice variants in ovarian adenocarcinoma by RT-PCR followed by detection of amplicons with the Southern technique and by immunoblot in 32 malignant and benign epithelial ovarian tumour specimens and 3 ovarian adenocarcinoma cell lines (A2780, 2008, OVCAR-3). p73alpha mRNA was expressed in all 17 ovarian cancer specimens, and 14 of 17 expressed at least 3 splice variants. In contrast, a different expression pattern was present in the ovarian adenomas: p73alpha was detected in 6 of 12 benign tumours, and only 1 adenoma expressed 3 splice variants. p73 protein was expressed in 9 of 16 ovarian cancer specimens, in all cell lines and in 1 of 3 borderline tumours. In contrast, none of 9 ovarian adenomas expressed detectable amounts of p73 protein. Expression of p73 mRNA and protein was not correlated with FIGO stage and histological grade, but we observed a significant correlation with over-expression of p53 protein. In summary, epithelial ovarian cancers express a more complex p73 isoform pattern and higher levels of p73 mRNA and protein than ovarian adenomas. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10962441

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Transcriptional activities of p73 splicing variants are regulated by inter-variant association.

Authors:  Y Ueda; M Hijikata; S Takagi; T Chiba; K Shimotohno
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

2.  The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer.

Authors:  Da Wang; Changlong Li; Xuemei Zhang
Journal:  DNA Cell Biol       Date:  2014-05-19       Impact factor: 3.311

3.  Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk.

Authors:  Lan Wang; Rui Gao; Long Yu
Journal:  Mol Biol Rep       Date:  2011-05-27       Impact factor: 2.316

4.  The Notch pathway in ovarian carcinomas and adenomas.

Authors:  O Hopfer; D Zwahlen; M F Fey; S Aebi
Journal:  Br J Cancer       Date:  2005-09-19       Impact factor: 7.640

5.  Interplay between TAp73 Protein and Selected Activator Protein-1 (AP-1) Family Members Promotes AP-1 Target Gene Activation and Cellular Growth.

Authors:  Deepa Subramanian; Wilawan Bunjobpol; Kanaga Sabapathy
Journal:  J Biol Chem       Date:  2015-05-27       Impact factor: 5.157

6.  TP73 is a credible biomarker for predicting clinical progression and prognosis in cervical cancer patients.

Authors:  Hui Ye; Xia Guo
Journal:  Biosci Rep       Date:  2019-08-05       Impact factor: 3.840

7.  Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs.

Authors:  Elena Makino; Vanessa Gutmann; Corinna Kosnopfel; Heike Niessner; Andrea Forschner; Claus Garbe; Tobias Sinnberg; Birgit Schittek
Journal:  Cell Death Dis       Date:  2018-09-11       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.